FFR

DANAMI 3-PRIMULTI Substudy – Complete Revascularization Guided by FFR Improves Prognosis in STEMI Patients with Severe Nonculprit Lesions

by
DANAMI 3-PRIMULTI Substudy - Complete Revascularization Guided by FFR Improves Prognosis in STEMI Patients with Severe Nonculprit Lesions

Research Background In patients with ST-segment elevation myocardial infarction (STEMI), approximately 50% have multivessel disease (MVD), which is associated with a poor prognosis, especially when there are three-vessel lesions or chronic total occlusions. Although emergency PCI is the standard treatment for STEMI, there is still controversy regarding the management strategy for nonculprit lesions (complete revascularization … Read more

Subgroup Analysis of DANAMI-3-PRIMULTI: The Impact of Age on Prognosis After Complete Revascularization

by
Subgroup Analysis of DANAMI-3-PRIMULTI: The Impact of Age on Prognosis After Complete Revascularization

Research Background With the increasing number of elderly patients receiving primary percutaneous coronary intervention (PPCI), the management strategies for non-culprit lesions have become controversial. Although multiple studies support that complete revascularization (treating all significant stenosed vessels) can improve prognosis, the benefits for elderly patients (≥75 years) remain unclear due to their comorbidities and shorter life … Read more

Analysis of Lesion Characteristics in the DANAMI-3-PRIMULTI Substudy

by
Analysis of Lesion Characteristics in the DANAMI-3-PRIMULTI Substudy

Research Background and Objectives The DANAMI-3-PRIMULTI trial has confirmed that in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD), fractional flow reserve (FFR)-guided complete revascularization (FFR-CRV) can significantly reduce the need for subsequent ischemia-driven revascularization (ID-RV), but it has no significant impact on mortality or reinfarction. The core questions of this substudy: … Read more